Table 2.
Number of available biological samples by baseline risk-subgroups, SCREEN-RA cohort, Switzerland, 2009–2020
| Baseline risk-group | Participants (n subjects) |
Serum samples (n samples) |
At least two sequential serum samples (n subjects) | DNA samples (n samples) |
RNA samples (n samples) |
Matched RNA and DNA (n samples) |
| 1 | 1006 | 1293 | 171 | 1060 | 839 | 835 |
| 2 | 80 | 242 | 59 | 152 | 140 | 140 |
| 3 | 147 | 379 | 92 | 227 | 213 | 213 |
| 4 | 143 | 222 | 57 | 149 | 125 | 124 |
| 5 | 51 | 133 | 32 | 82 | 84 | 84 |
Baseline risk-groups as defined in figure 2.
SCREEN-RA, Evaluation of a SCREENing strategy for Rheumatoid Arthritis.